通过利用CLEC9A增强癌症疫苗的免疫原性。
Enhancing the immunogenicity of cancer vaccines by harnessing CLEC9A.
作者信息
Lahoud M H, Radford K J
机构信息
Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia.
Cancer Immunotherapies Laboratory, Mater Research Institute, University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, Australia.
出版信息
Hum Vaccin Immunother. 2022 Dec 31;18(1):1873056. doi: 10.1080/21645515.2021.1873056. Epub 2021 Feb 24.
Dendritic cell (DC) vaccines are a safe and effective means of inducing tumor immune responses, however, a better understanding of DC biology is required in order to realize their full potential. Recent advances in DC biology have identified a crucial role for cDC1 in tumor immune responses, making this DC subset an attractive vaccine target. Human cDC1 exclusively express the C-type-lectin-like receptor, CLEC9A (DNGR-1) that plays an important role in cross-presentation, the process by which effective CD8 T cell responses are generated. CLEC9A antibodies deliver antigen specifically to cDC1 for the induction of humoral, CD4 and CD8 T cell responses and are therefore promising candidates to develop as vaccines for infectious diseases and cancer. The development of human CLEC9A antibodies now facilitates their application as vaccines for cancer immunotherapy. Here we discuss the recent advances in CLEC9A targeting antibodies as vaccines for cancer and their translation to the clinic.
树突状细胞（DC）疫苗是诱导肿瘤免疫反应的一种安全有效的手段，然而，为了充分发挥其潜力，需要对DC生物学有更深入的了解。DC生物学的最新进展已确定cDC1在肿瘤免疫反应中起关键作用，使这一DC亚群成为有吸引力的疫苗靶点。人类cDC1特异性表达C型凝集素样受体CLEC9A（DNGR-1），其在交叉呈递中起重要作用，交叉呈递是产生有效的CD8 T细胞反应的过程。CLEC9A抗体将抗原特异性递送至cDC1以诱导体液免疫、CD4和CD8 T细胞反应，因此是开发传染病和癌症疫苗的有前景的候选物。人CLEC9A抗体的开发现在促进了其作为癌症免疫治疗疫苗的应用。在此，我们讨论靶向CLEC9A的抗体作为癌症疫苗的最新进展及其向临床的转化。
Zotero 插件